TET2 and acute myeloid leukemia: Several studies have shown that the frequency of TET2 mutations in Asian MDS patients is significantly lower than that in Western populations, at 17.5 and 28.9%, respectively, and that the frequency of TET2 mutations remains stable during disease progression to AML (31, 32).